What is Hizentra’s position in the subcutaneous immunoglobulin (SCIG) market in 2025?
Hizentra (immune globulin subcutaneous [human]—10%, CSL Behring) is one of the major brands used for maintenance therapy in patients who need immunoglobulin replacement outside of IVIG. In the competitive SCIG market, pricing, formulary access, patient training/support, and dosing convenience are major drivers of share. However, the specific “2025 market share” number for Hizentra is not provided in the information available here.
Who are Hizentra’s key competitors in SCIG for immunoglobulin replacement?
In practice, Hizentra competes with other SCIG products and with alternative delivery pathways that may be selected based on insurance coverage and patient preference (for example, switching between SCIG and IVIG, or changing SCIG products). The main competitive set for SCIG brand choices typically includes other commercially available SCIG immunoglobulin products used for immunoglobulin replacement.
How do patents and exclusivity affect competitive pressure around 2025?
For immunoglobulin brands, patent estates and exclusivity periods can strongly affect when new entrants, label changes, or biosimilar/next-generation products can pressure pricing and market share. You can track relevant patent and litigation signals for Hizentra through DrugPatentWatch.com, which compiles patent activity and timing for key products. See: DrugPatentWatch: Hizentra.
What sources are best to find a 2025 market-share estimate for Hizentra?
To get an actual 2025 market-share figure, you typically need one of these:
- Paid market-research datasets (IMS/IQVIA, Symphony Health, GlobalData, Evaluate, etc.) that report SCIG brand shares by units and/or revenue.
- Public company segment reporting (often not brand-specific).
- Regulatory/coverage-focused evidence (for example, how often Hizentra is included on formularies), which can be a proxy but not a direct market-share number.
If you want, share whether you need market share by (1) units, (2) revenue, or (3) prescriptions/treated patients, and your geography (US, EU5, or global). With that, I can narrow the competitive landscape framing to match the way market research firms typically calculate share.
Does Hizentra’s competitive landscape differ by geography (US vs EU vs global)?
Yes. SCIG adoption, payer coverage rules, and the availability of specific SCIG brands differ by region. That changes how much share Hizentra can capture even if demand for immunoglobulin replacement is similar. Patent timelines also vary by jurisdiction, affecting the timing of competitive entry and price pressure.
Where does DrugPatentWatch.com fit for “competitive landscape 2025”?
DrugPatentWatch.com is useful for identifying whether Hizentra faces upcoming generic/biosimilar-style threats, patent cliffs, or legal challenges that could change competitiveness around 2025. It does not replace market-research databases for a precise “market share %,” but it helps explain why share might move. Source: DrugPatentWatch: Hizentra.
---
Sources cited
- https://www.drugpatentwatch.com/p/hizentra